Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Edicotinib||JNJ-40346527||CSF1R Inhibitor 23||Edicotinib (JNJ-40346527) is a small molecule inhibitor of CSF1R, which may inhibit growth of CSF1R-expressing tumor cells (PMID: 25628399).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Hodgkin's lymphoma||not applicable||Edicotinib||Phase II||Actionable||In a Phase II/III clinical trial, JNJ-40346527 demonstrated safety some efficacy, with complete response in 5.0% (1/20), partial response in 5.0% (1/20), and stable disease in 55.0% (11/20) of patients with refractory Hodgkin's lymphoma (PMID: 25628399).||25628399|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03557970||Phase II||Edicotinib||CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia||Active, not recruiting|
|NCT03177460||Phase I||Daratumumab Edicotinib||Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer||Active, not recruiting|